Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menitorix + Infanrix Penta
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
IH + Hib-MenC/NVC refers to a combination vaccine regimen consisting of the co-administration of two GlaxoSmithKline (GSK) products: **Menitorix** and **Infanrix Penta**. Menitorix is a combined conjugate vaccine containing Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroup C (MenC) antigens, both conjugated to a tetanus toxoid carrier. Infanrix Penta is a pentavalent vaccine that protects against diphtheria, tetanus, acellular pertussis (DTPa), hepatitis B (HBV), and inactivated poliovirus (IPV). This combination regimen is used in pediatric immunization schedules to provide comprehensive protection against seven infectious diseases. It was evaluated in Phase 3 clinical trials to demonstrate that the co-administration of these vaccines is safe and maintains the immunogenicity of all individual components compared to other standard-of-care combinations like Infanrix Hexa.
- Brand names
- MenitorixInfanrix Penta
- Other names
- Hib-MenC-TT co-administered with DTPa-HBV-IPVCombined Hib-MenC vaccine co-administered with DTPa-HBV-IPV vaccine
02
Targets
PRNP (Cellular Prion Protein)Neisseria meningitidis group C capsular polysaccharideHBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Menitorix + Infanrix Penta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menitorix + Infanrix Penta.